Validación del ensayo de butirilcolinesterasa para la evaluación de agentes anticolinesterásicos a partir de matrices naturales

Abstract

Abstract: Neurodegenerative diseases mainly affect the central nervous system, which are characterized by a progressive neuronal loss in specific areas of the brain. At present it is known that there are more than 100 types which stand out: Alzheimer's (EA), Parkinson's (PD) among others. For the treatment of AD, some drugs such as: donepezil, rivastigmine. This study is focused on testing enzymatic with the butyrylcholinesterase enzyme, both with the 50mM tris buffer pH 8.0 and the BPS 50mM pH 7.4, the same as those performed under the Ellman method and the methodology from the bioassay laboratory. For the comparative analysis of the results, we used the statistical program "Graph Pad Prism v8.0.1" the same ones that showed that there is no significant difference between the tris buffer and the PBS buffer since in both, the absorption maximum was 3.59, reaching the conclusion that to perform the effectiveness with the inhibitor donepezil, it can be done with either of the two. The IC50 of donepezil was 2.4 µM.